23Jun 2020
The study result of “CA102N suppresses the growth of mouse colon cancer by inhibition of PI3K pathway and immune modulation” will be presented during the Annual Meeting of American Association of Cancer Research
read more
17Jun 2019
Holy Stone Healthcare Co., Ltd. attended 2019 BIO International Convention in Philadelphia, USA on June 3-6.
read more
09Apr 2019
Holy Stone Healthcare participates in the Atlanta 2019 AACR Annual Meeting (2019/3/29-4/3) poster presentation.
read more

Vision & Mission

We are committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients worldwide. Our mission is to create innovative therapeutic products based on hyaluronic acid using our know-how and experience to address unmet clinical needs with superior tolerability and efficacy.


We are focused on development of new drugs and medical devices, especially hyaluronic acid related therapeutic products.